- Home
- ALNY
as 10-08-2025 3:38pm EST
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 59.6B | IPO Year: | 2004 |
| Target Price: | $448.97 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 29 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $205.87 - $484.21 | Next Earning Date: | 10-30-2025 |
| Revenue: | $2,461,963,000 | Revenue Growth: | 5.01% |
| Revenue Growth (this year): | 59.55% | Revenue Growth (next year): | 40.90% |
Stock Insider Trading Activity of Alnylam Pharmaceuticals Inc. (ALNY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Garg Pushkal | ALNY | EVP Chief R&D | Oct 3 '25 | Sell | $452.05 | 3,022 | $1,364,387.18 | 21,751 | |
| Fitzgerald Kevin Joseph | ALNY | CSO & EVP, Head of Research | Oct 2 '25 | Sell | $452.32 | 2,441 | $1,103,451.46 | 26,723 | |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Oct 2 '25 | Sell | $452.32 | 8,924 | $4,034,084.66 | 66,826 | |
| Garg Pushkal | ALNY | EVP Chief R&D | Oct 2 '25 | Sell | $452.32 | 2,937 | $1,327,674.71 | 21,751 | |
| Tanguler Tolga | ALNY | EVP, Chief Commercial Officer | Oct 2 '25 | Sell | $452.32 | 1,405 | $635,126.28 | 27,818 | |
| Poulton Jeffrey V. | ALNY | EVP, Chief Financial Officer | Oct 2 '25 | Sell | $452.32 | 3,821 | $1,727,283.60 | 54,247 | |
| Reitan Colleen F | ALNY | Director | Sep 9 '25 | Sell | $469.51 | 18,000 | $8,416,729.64 | 800 | |
| Tanguler Tolga | ALNY | EVP, Chief Commercial Officer | Aug 29 '25 | Sell | $449.02 | 3,474 | $1,557,649.44 | 27,818 | |
| Garg Pushkal | ALNY | EVP Chief R&D | Aug 19 '25 | Sell | $458.88 | 1,455 | $666,987.16 | 21,751 | |
| Fitzgerald Kevin Joseph | ALNY | CSO & EVP, Head of Research | Aug 18 '25 | Sell | $452.31 | 1,396 | $632,758.71 | 26,723 |
Latest Alnylam Pharmaceuticals Inc. News
ALNY Breaking Stock News: Dive into ALNY Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Discover 3 Stocks Including ConnectOne Bancorp Priced Below Estimated Value
Simply Wall St.
2 days ago
Discovering Bank First And 2 More Stocks That May Be Trading Below Their Estimated Value
Simply Wall St.
3 days ago
3 Stocks Estimated To Be Trading At Discounts Of Up To 42.8%
MT Newswires
3 days ago
Morgan Stanley Raises Price Target on Alnylam Pharmaceuticals to $475 From $405, Keeps Equalweight Rating
Argus Research
3 days ago
Daily – Vickers Top Buyers & Sellers for 10/06/2025
Simply Wall St.
4 days ago
Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Set To Breakeven
MT Newswires
5 days ago
Alnylam Pharmaceuticals Insider Sold Shares Worth $2,692,062, According to a Recent SEC Filing
MT Newswires
5 days ago
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,103,451, According to a Recent SEC Filing
Compare ALNY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALNY Alnylam Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.